Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 1 950 GBX 4.17% Market Closed
Market Cap: 4.3B GBX
Have any thoughts about
Hikma Pharmaceuticals PLC?
Write Note

Hikma Pharmaceuticals PLC
Net Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hikma Pharmaceuticals PLC
Net Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
Hikma Pharmaceuticals PLC
LSE:HIK
Net Income
$367m
CAGR 3-Years
-15%
CAGR 5-Years
-1%
CAGR 10-Years
-1%
GlaxoSmithKline PLC
LSE:GSK
Net Income
ÂŁ4.3B
CAGR 3-Years
-1%
CAGR 5-Years
-2%
CAGR 10-Years
-1%
AstraZeneca PLC
LSE:AZN
Net Income
$7.7B
CAGR 3-Years
21%
CAGR 5-Years
30%
CAGR 10-Years
13%
Verona Pharma PLC
NASDAQ:VRNA
Net Income
-$153.7m
CAGR 3-Years
-60%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Net Income
-$189m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dechra Pharmaceuticals PLC
LSE:DPH
Net Income
ÂŁ6.3m
CAGR 3-Years
-51%
CAGR 5-Years
-29%
CAGR 10-Years
-10%
No Stocks Found

Hikma Pharmaceuticals PLC
Glance View

Market Cap
4.3B GBX
Industry
Pharmaceuticals

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. The firm is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The firm operates through three segments, such as Injectables, Generics and Branded. The Injectables business develops and manufactures generic injectable products, which are primarily used in hospitals. The Generics business develops and manufactures oral and other non-injectable generic products. The Branded business develops and manufactures branded generics and markets and sells in-licensed patented products in Middle East/North Africa (MENA). The Company’s products are sold in the retail and hospital markets. The company also markets its products in Canada, which includes approximately 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products.

HIK Intrinsic Value
3 724.01 GBX
Undervaluation 48%
Intrinsic Value
Price

See Also

What is Hikma Pharmaceuticals PLC's Net Income?
Net Income
367m USD

Based on the financial report for Jun 30, 2024, Hikma Pharmaceuticals PLC's Net Income amounts to 367m USD.

What is Hikma Pharmaceuticals PLC's Net Income growth rate?
Net Income CAGR 10Y
-1%

Over the last year, the Net Income growth was 67%. The average annual Net Income growth rates for Hikma Pharmaceuticals PLC have been -15% over the past three years , -1% over the past five years , and -1% over the past ten years .

Back to Top